GPC3 and hepatocellular carcinoma: In two sequential phase I studies, 13 patients with advanced GPC3-positive HCC, determined by immunohistochemistry, received escalating doses of anti-GPC3 CAR T cells after lymphodepletion with cyclophosphamide with or without fludarabine [109].